• 본문 바로가기(Skip Contents)
ENGLISH
  • KOREAN
  • HOME

corestem

  • ABOUT US
    • Overview
    • History
    • Manufacturing facility
    • Our Company
  • PRODUCT
    • ALS (NeuroNata-R®)
    • Lou Gehrig's disease
  • PIPELINE
    • Pipeline
    • SLE
    • CA
  • R&D
    • Stem Cell Therapy
  • IR
    • Stock Information
    • Disclosures
    • Finances
    • Announcement of Settlement
    • IR Inquiry
  • PR
    • Press Report
    • Notice
    • Media
    • Online Inquiry

전체메뉴

전체메뉴

  • ABOUT US

    Overview History Manufacturing facility Our Company
  • PRODUCT

    ALS (NeuroNata-R®) Lou Gehrig's disease
  • PIPELINE

    Pipeline SLE CA
  • R&D

    Stem Cell Therapy
  • IR

    Stock Information Disclosures Finances Announcement of Settlement IR Inquiry
  • PR

    Press Report Notice Media Online Inquiry
  • HOME
ENGLISH
  • KOREAN
  • ABOUT US
    • Overview
    • History
    • Manufacturing facility
    • Our Company
  • PRODUCT
    • ALS (NeuroNata-R®)
    • Lou Gehrig's disease
  • PIPELINE
    • Pipeline
    • Target Disease
    • Lupus
  • R&D
    • Stem Cell Therapy
  • IR
    • Stock Information
    • Disclosures
    • Finances
    • Announcement of Settlement
    • IR Inquiry
  • PR
    • Press Report
    • Notice
    • Media
    • Online Inquiry

PR

Corestem is a biopharmaceutical company that researches and commercializes stem cell technology.

  • Press Report
  • Notice
  • Media
  • Online Inquiry
  • Press Report
  • Notice
  • Media
  • Online Inquiry

언론보도

  • 2022.05.02
    코아스템, 핀테라퓨틱스와 공동 연구개발 협약

    코아스템, 핀테라퓨틱스와 공동 연구개발 협약입력 2022-05-02 08:56수정 2022-05-02 08..

  • 2022.03.25
    '소뇌실조증' 치료목적 첨단의료기술개발 최종평가 결과 ..

    ‘소뇌실조증‘ 치료목적 첨단의료기술개발 최종평가 결과 ‘우수’ 선정임상을 통해 치료에 대한 유의미한 결과 도..

  • 2022.01.26
    코아스템, 시신경척수염 줄기세포藥 ‘치료목적 사용’ ..

    코아스템, 시신경척수염 줄기세포藥 ‘치료목적 사용’ 재승인입력 2022-01-26 13:41수정 2022..

  • 2021.12.17
    코아스템, ‘2022 JP모건 헬스케어 컨퍼런스’ 참가

    코아스템, ‘2022 JP모건 헬스케어 컨퍼런스’ 참가입력 2021-12-17 16:05수정 2021-12-..

  • 2021.11.12
    김경숙 코아스템 대표 "뉴로나타-알주 임상3상..

    김경숙 코아스템 대표 "뉴로나타-알주 임상3상 계획대로 진행중…기술이전 논의도 활발"환자..

  • 2021.11.01
    루게릭병 약 '뉴로나타-알주' 조건부허가 기간 연장

    루게릭병 약 '뉴로나타-알주' 조건부허가 기간 연장중앙약심 회의록 공개, 코아스템社 임상 변경 타당성 인..

  • 1
  • 2
  • 3
  • 4
  • 5
  • ABOUT US
    Overview History Manufacturing facility Our Company
  • PRODUCT
    ALS (NeuroNata-R®) Lou Gehrig's disease
  • PIPELINE
    Pipeline Target Disease Lupus
  • R&D
    Stem Cell Therapy
  • IR
    Stock Information Disclosures Finances Announcement of Settlement IR relations
  • PR
    Press Report Notice Media Online Inquiry

Contact Information
  • 24, Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
  • Gen (02) 497-3711
  • IR DID 070-4706-3546
  • FAX (02) 6349-8666
  • E-MAIL corestem@corestem.com
Copyright 2018 CORESTEM, Inc All right reserved.